Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | RGNX |
---|---|---|
09:32 ET | 5087 | 10.91 |
09:34 ET | 4993 | 10.99 |
09:36 ET | 4472 | 11.1016 |
09:38 ET | 3100 | 11.22 |
09:39 ET | 1608 | 11.1 |
09:41 ET | 1251 | 10.97 |
09:43 ET | 1598 | 10.93 |
09:48 ET | 1957 | 11.01 |
09:50 ET | 2433 | 10.97 |
09:52 ET | 2260 | 10.885 |
09:56 ET | 826 | 10.97 |
09:57 ET | 200 | 10.97 |
09:59 ET | 1500 | 11.0049 |
10:01 ET | 2322 | 10.94 |
10:03 ET | 1200 | 10.915 |
10:06 ET | 1900 | 10.935 |
10:08 ET | 2610 | 10.94 |
10:10 ET | 1620 | 10.96 |
10:12 ET | 900 | 11 |
10:14 ET | 900 | 10.96 |
10:15 ET | 4110 | 10.955 |
10:17 ET | 2463 | 10.92 |
10:19 ET | 800 | 10.91 |
10:21 ET | 2320 | 10.95 |
10:24 ET | 1126 | 10.93 |
10:26 ET | 1000 | 10.975 |
10:28 ET | 1400 | 10.935 |
10:30 ET | 1700 | 10.94 |
10:32 ET | 2361 | 10.96 |
10:33 ET | 400 | 10.96 |
10:35 ET | 200 | 10.97 |
10:37 ET | 1400 | 10.94 |
10:39 ET | 1700 | 10.97 |
10:42 ET | 600 | 10.955 |
10:44 ET | 1920 | 10.97 |
10:46 ET | 570 | 10.97 |
10:48 ET | 825 | 10.97 |
10:50 ET | 2976 | 10.98 |
10:51 ET | 400 | 10.99 |
10:53 ET | 1604 | 10.98 |
10:55 ET | 100 | 10.985 |
10:57 ET | 2517 | 10.985 |
11:00 ET | 400 | 10.97 |
11:02 ET | 400 | 10.96 |
11:04 ET | 2776 | 10.92 |
11:06 ET | 1593 | 10.9154 |
11:08 ET | 100 | 10.92 |
11:09 ET | 750 | 10.9 |
11:11 ET | 828 | 10.87 |
11:13 ET | 300 | 10.875 |
11:15 ET | 2074 | 10.85 |
11:20 ET | 200 | 10.845 |
11:24 ET | 300 | 10.81 |
11:26 ET | 400 | 10.8 |
11:27 ET | 500 | 10.81 |
11:29 ET | 1632 | 10.78 |
11:31 ET | 1104 | 10.77 |
11:33 ET | 2025 | 10.73 |
11:36 ET | 1305 | 10.75 |
11:38 ET | 100 | 10.8 |
11:40 ET | 500 | 10.75 |
11:42 ET | 200 | 10.745 |
11:44 ET | 200 | 10.73 |
11:45 ET | 905 | 10.71 |
11:47 ET | 700 | 10.705 |
11:51 ET | 1912 | 10.65 |
11:54 ET | 300 | 10.65 |
11:56 ET | 4237 | 10.64 |
11:58 ET | 1100 | 10.65 |
12:00 ET | 400 | 10.66 |
12:02 ET | 2095 | 10.66 |
12:03 ET | 5103 | 10.66 |
12:05 ET | 1450 | 10.695 |
12:07 ET | 1000 | 10.71 |
12:09 ET | 200 | 10.68 |
12:12 ET | 100 | 10.62 |
12:14 ET | 400 | 10.63 |
12:16 ET | 1900 | 10.645 |
12:18 ET | 700 | 10.63 |
12:20 ET | 553 | 10.62 |
12:21 ET | 3390 | 10.695 |
12:23 ET | 2700 | 10.71 |
12:25 ET | 826 | 10.68 |
12:27 ET | 1154 | 10.69 |
12:30 ET | 2602 | 10.7 |
12:32 ET | 950 | 10.7 |
12:34 ET | 500 | 10.7 |
12:36 ET | 188 | 10.7 |
12:38 ET | 3020 | 10.73 |
12:39 ET | 607 | 10.71 |
12:41 ET | 100 | 10.71 |
12:43 ET | 3116 | 10.745 |
12:45 ET | 3128 | 10.75 |
12:48 ET | 1426 | 10.775 |
12:50 ET | 100 | 10.75 |
12:52 ET | 200 | 10.74 |
12:54 ET | 556 | 10.725 |
12:56 ET | 2700 | 10.735 |
12:59 ET | 482 | 10.7 |
01:01 ET | 750 | 10.695 |
01:03 ET | 1541 | 10.685 |
01:06 ET | 4574 | 10.7 |
01:08 ET | 200 | 10.7 |
01:10 ET | 1700 | 10.71 |
01:12 ET | 1090 | 10.67 |
01:14 ET | 313 | 10.645 |
01:15 ET | 3099 | 10.65 |
01:17 ET | 650 | 10.64 |
01:19 ET | 455 | 10.64 |
01:21 ET | 100 | 10.64 |
01:24 ET | 100 | 10.64 |
01:26 ET | 3016 | 10.68 |
01:32 ET | 700 | 10.66 |
01:33 ET | 6397 | 10.68 |
01:35 ET | 2586 | 10.67 |
01:37 ET | 930 | 10.6615 |
01:39 ET | 1100 | 10.68 |
01:46 ET | 1606 | 10.64 |
01:48 ET | 300 | 10.615 |
01:50 ET | 4598 | 10.63 |
01:51 ET | 1200 | 10.64 |
01:53 ET | 1000 | 10.65 |
01:57 ET | 400 | 10.64 |
02:00 ET | 500 | 10.61 |
02:02 ET | 200 | 10.61 |
02:04 ET | 5829 | 10.65 |
02:06 ET | 800 | 10.65 |
02:08 ET | 5157 | 10.64 |
02:09 ET | 1716 | 10.62 |
02:11 ET | 1873 | 10.61 |
02:13 ET | 1978 | 10.62 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Regenxbio Inc | 536.9M | -1.8x | --- |
Y-mAbs Therapeutics Inc | 500.3M | -23.1x | --- |
SAGE Therapeutics Inc | 648.8M | -1.3x | --- |
Grail Inc | 403.6M | -0.3x | --- |
Alector Inc | 423.1M | -3.3x | --- |
Urogen Pharma Ltd | 653.8M | -4.7x | --- |
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $536.9M |
---|---|
Revenue (TTM) | $86.7M |
Shares Outstanding | 49.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.26 |
EPS | $-5.88 |
Book Value | $7.08 |
P/E Ratio | -1.8x |
Price/Sales (TTM) | 6.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -306.52% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.